U.S. market Closed. Opens in 1 hour 11 minutes

HALO | Halozyme Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for HALO we got that it has strong fundamentals where Valuation is considered to be slightly undervalued, Profitability is stunning wealthy, Growth is exceptionally good and Health is strong.

Valuation (66%)

Company Industry
P/E Ratio (TTM) 18.56 -23.05
PEG Ratio (TTM) 2.85 15.47
P/S Ratio (TTM) 7.14 49.46
P/B Ratio (TTM) 21.63 18.87
P/FCF Ratio (TTM) 15.28 -3.27
Price to 5YR AVG Earnings Ratio 35.57 -3.55
Price to 5YR AVG FCF Ratio 35.85 -9.37

Profitability (90%)

Company Industry
ROA (TTM) 17.13% -5.14%
ROE (TTM) 168.60% 16.69%
Net Profit Margin (TTM) 38.62% -1,583.93%
ROIC 5YR AVG 20.66% 15.15%

Growth (93%)

4QTR AVG 3YR AVG 5YR AVG
EPS 6.83% 167.26% 99.49%
Revenue 1.87% 43.75% 41.16%
Net Income 6.29% 166.91% 98.05%
Cash Flow 11.24% 177.44% 114.87%

Health (65%)

Company Industry
Current Ratio (TTM) 7.41 6.13
Quick Ratio (TTM) 6.21 5.85
D/E Ratio (TTM) 5.30 -15.81
Interest Coverage (TTM) 21.44 -1.57
Piotroski F-Score 7 5
Altman Z-Score 4.11 14.12
LTL to 5YR AVG FCF 8.62 0.17
Shares Outstanding Growth 5YR AVG -1.63% 123.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙